TDOC vs HIMS Stock Comparison: AI Score, Valuation, Performance and Upside
TDOC (Teladoc Health) and HIMS (Hims & Hers) are both telehealth companies but with very different models — Teladoc is the B2B enterprise telehealth platform serving employers and health plans with comprehensive virtual care, while Hims & Hers is a consumer-direct health brand destigmatizing and subscription-izing men's and women's health categories. Teladoc is larger and more comprehensive; Hims & Hers is faster-growing and more consumer-brand focused.
TDOC vs HIMS is enterprise B2B virtual care platform (Teladoc's employer and insurance channel) versus consumer-direct branded health subscription business (Hims & Hers' destigmatized men's and women's health) — both in telehealth but fundamentally different go-to-market strategies and business models.
TDOC holds the edge across 3 of 5 key metrics in this comparison. TDOC has delivered stronger 1-year price return (-23.73% vs -50.20%), though HIMS has the better forward P/E setup (29.03x vs -8.23x for TDOC). On fundamentals, HIMS is growing revenue faster (38.20%), while TDOC maintains the higher operating margin (-5.68%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for TDOC (+18.68%) than for HIMS (+7.36%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want the largest virtual care platform serving employer and health plan markets with comprehensive mental health (BetterHelp), primary care, and chronic condition management
- Value Teladoc's B2B enterprise channel as a lower customer acquisition cost model versus consumer-direct advertising-dependent telehealth companies
- See Teladoc's integrated care vision (one platform for all virtual health needs) as the logical destination for employers seeking to consolidate telehealth vendor relationships
- Want a consumer health brand with high subscriber growth driven by destigmatized men's and women's health products and subscription medication management
- Value Hims & Hers' brand differentiation in health categories (ED, hair loss, mental health) that traditional pharmaceutical companies have not marketed effectively to consumers
- See category expansion (GLP-1, primary care, women's health) as a significant revenue growth opportunity as Hims scales its consumer health brand
| Metric | TDOC | HIMS |
|---|---|---|
| AI scorei | 24.8 | 42.7 |
| AI ranki | #3063 | #926 |
| Latest closei | $6.30 | $27.99 |
| 1M returni | -5.41% | -9.97% |
| 6M returni | +17.76% | +27.11% |
| 1Y returni | -23.73% | -50.20% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | TDOC | HIMS |
|---|---|---|
| 1Y ago | $7.63K (-23.7%) started 2025-09-18 | $4.98K (-50.2%) started 2025-09-18 |
| 5Y ago | $464.88 (-95.4%) started 2021-09-20 | $34.77K (+247.7%) started 2021-09-20 |
| 10Y ago | $3.33K (-66.7%) started 2016-09-19 | $28.56K (+185.6%) started 2019-09-13 |
Hypothetical — past performance does not guarantee future results.
| Metric | TDOC | HIMS |
|---|---|---|
| Market capi | $1.17B | $6.79B |
| Trailing P/Ei | N/A | N/A |
| Forward P/Ei | -8.23 | 29.03 |
| Price/Salesi | N/A | N/A |
| EV/Revenuei | 0.56 | 2.85 |
| Analyst targeti | $7.67 | $31.23 |
| Target upsidei | +18.68% | +7.36% |
| Metric | TDOC | HIMS |
|---|---|---|
| Revenue growthi | -4.00% | 38.20% |
| Earnings growthi | N/A | N/A |
| EPS growthi | N/A | N/A |
| FCF margini | +7.67% | +32.95% |
| Operating margini | -5.68% | -12.75% |
| Profit margini | -7.13% | -5.51% |
| ROIC proxyi | -12.98% | -32.03% |
| Return on equityi | -12.98% | -32.03% |
| Dividend yieldi | N/A | N/A |
| Payout ratioi | 0.00% | 0.00% |
| Dividend growth streaki | N/A | N/A |
| Betai | 2.13 | 2.42 |
| Debt/equityi | 79.09 | 477.13 |
| Current ratioi | 0.83 | 0.93 |
| Quick ratioi | 0.73 | 0.82 |
Over the past year, TDOC and HIMS have moved weakly in the same direction (correlation of 0.25), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | TDOC | HIMS |
|---|---|---|---|
| 1Y | Growthi | -23.73% | -50.20% |
| CAGRi | -23.74% | -50.22% | |
| Volatilityi | 63.79% | 91.54% | |
| Sharpe ratioi | -0.17 | -0.37 | |
| Sortino ratioi | -0.23 | -0.58 | |
| Max drawdowni | 52.75% | 76.86% | |
| Current drawdowni | 35.19% | 55.40% | |
| Avg drawdowni | 26.32% | 48.39% | |
| Ulcer Indexi | 30.08% | 51.55% | |
| Max daily dropi | 28.32% | 16.03% | |
| Max wkly dropi | 28.31% | 32.71% | |
| 5Y | Growthi | -95.35% | +247.70% |
| CAGRi | -45.91% | +28.34% | |
| Volatilityi | 65.52% | 84.20% | |
| Sharpe ratioi | -0.67 | 0.66 | |
| Sortino ratioi | -0.92 | 1.03 | |
| Max drawdowni | 97.10% | 78.88% | |
| Current drawdowni | 95.92% | 59.28% | |
| Avg drawdowni | 83.25% | 32.05% | |
| Ulcer Indexi | 85.58% | 37.28% | |
| Max daily dropi | 40.15% | 34.63% | |
| Max wkly dropi | 43.25% | 39.06% | |
| 10Y | Growthi | -66.67% | +185.61% |
| CAGRi | -10.41% | +16.14% | |
| Volatilityi | 60.77% | 77.59% | |
| Sharpe ratioi | 0.05 | 0.52 | |
| Sortino ratioi | 0.08 | 0.80 | |
| Max drawdowni | 98.48% | 87.29% | |
| Current drawdowni | 97.86% | 59.28% | |
| Avg drawdowni | 53.72% | 43.66% | |
| Ulcer Indexi | 66.77% | 52.12% | |
| Max daily dropi | 40.15% | 34.63% | |
| Max wkly dropi | 43.25% | 39.06% |
| Category | TDOC | HIMS |
|---|---|---|
| Company | Teladoc Health, Inc. | Hims & Hers Health, Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Health Information Services | Drug Manufacturers - Specialty & Generic |
| Core business | Teladoc Health is the world's largest virtual care company, providing telehealth services including primary care, mental health (BetterHelp), chronic condition management (Livongo, for diabetes, hypertension), and specialty care through employer benefits and health insurance channels. | Hims & Hers is a consumer health company offering telehealth consultations and medications for men's health (erectile dysfunction, hair loss, premature ejaculation) and women's health (skincare, hair, sexual health, mental health) — focusing on destigmatizing and making accessible conditions that consumers have historically been reluctant to discuss with in-person doctors. |
| Investor focus | Investors track Teladoc's integrated care visit volume, BetterHelp therapy session growth and marketing efficiency, Livongo chronic condition program membership, revenue per member, and the path to profitability after heavy investment in building the integrated care platform. | Investors track Hims & Hers' subscriber count, average order value, category expansion (GLP-1 weight loss medications, mental health, primary care), revenue growth, and the sustainability of its subscription consumer health brand business model. |
- Market-leading virtual care platform with comprehensive health services across primary care, mental health, and chronic condition management in a single integrated offering
- Employer and health plan channel provides large enterprise customer contracts covering millions of covered lives — B2B2C distribution reduces consumer acquisition cost versus direct-to-consumer
- BetterHelp is the world's largest online therapy platform with millions of therapy clients globally
- Consumer brand power in the men's health and women's health categories — Hims has succeeded in destigmatizing ED and hair loss treatment through direct, non-clinical brand messaging
- Subscription model provides recurring revenue from ongoing medication refills — most Hims & Hers customers subscribe for months or years to ongoing prescriptions
- GLP-1 weight loss medication category (offering compounded semaglutide during drug shortage) rapidly expanded the addressable market and drove significant subscriber growth
- Teladoc's $18.5 billion acquisition of Livongo in 2020 has not delivered expected value — the company took a massive goodwill write-down and the integrated care cross-selling has been slower than expected
- BetterHelp marketing efficiency has declined — the consumer mental health market requires expensive direct-to-consumer advertising as the therapy category remains fragmented
- Telehealth reimbursement regulations are still evolving — Medicare and insurance coverage for virtual visits varies and adds uncertainty to the revenue model
- Hims & Hers's GLP-1 compounded drug business faces regulatory risk — the FDA ended the official drug shortage designation for Ozempic and Wegovy, which could limit the ability to compound generic versions
- Consumer-direct acquisition through social media advertising is expensive — Hims depends on paid social and digital marketing to acquire subscribers at sustainable economics
- Physician staffing and prescription practices in telehealth face ongoing regulatory scrutiny — prescribing standards for telehealth-only practitioners continue to evolve
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.